Figure 2

Kaplan–Meier curves of the clinical outcome for MTA3 regarding MTA3 immunolabelling. a: Schematic representation shows survival curves of lymph node metastatic group and non-metastatic group in patients with NSCLC (P = 0.000). b: Schematic representation shows survival curves of different MTA3 protein level groups in patients with NSCLC (P = 0.000). c: Schematic representation shows survival curves of different TNM stages in patients with NSCLC (P = 0.000). d: Schematic representation shows survival curves of different tumor stages in patients with NSCLC (P = 0.000). e: Schematic representation shows survival curves of different genders in patients with NSCLC (P = 0.516). f: Schematic representation shows survival curves of different ages in patients with NSCLC (P = 0.133). g: Schematic representation shows survival curves of different histology types in patients with NSCLC (P = 0.865). h: Schematic representation shows survival curves of differentiations in patients with NSCLC (P = 0.134).